• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Arch Otorhinolaryngol . Self-reported smell and taste recovery in coronavirus disease 2019 patients: a one-year prospective study

tetano

Editor, Senior Moderator
Eur Arch Otorhinolaryngol


. 2021 May 7.
doi: 10.1007/s00405-021-06839-w. Online ahead of print.
Self-reported smell and taste recovery in coronavirus disease 2019 patients: a one-year prospective study


Paolo Boscolo-Rizzo[SUP] 1 [/SUP], Francesco Guida[SUP] 2 [/SUP], Jerry Polesel[SUP] 3 [/SUP], Alberto Vito Marcuzzo[SUP] 2 [/SUP], Paolo Antonucci[SUP] 2 [/SUP], Vincenzo Capriotti[SUP] 4 [/SUP], Erica Sacchet[SUP] 2 [/SUP], Fiordaliso Cragnolini[SUP] 2 [/SUP], Andrea D'Alessandro[SUP] 2 [/SUP], Enrico Zanelli[SUP] 2 [/SUP], Riccardo Marzolino[SUP] 2 [/SUP], Chiara Lazzarin[SUP] 2 [/SUP], Margherita Tofanelli[SUP] 2 [/SUP], Nicoletta Gardenal[SUP] 2 [/SUP], Daniele Borsetto[SUP] 5 [/SUP], Claire Hopkins[SUP] 6 [/SUP], Luigi Angelo Vaira[SUP] 7 [/SUP], Giancarlo Tirelli[SUP] 2 [/SUP]



Affiliations

Abstract

Purpose: The aim of the present study was to estimate the 1 year prevalence and recovery rate of self-reported chemosensory dysfunction in a series of subjects with previous mild-to-moderate symptomatic COVID-19.
Methods: Prospective study based on the SNOT-22, item "sense of smell or taste" and additional outcomes.
Results: 268/315 patients (85.1%) completing the survey at baseline also completed the follow-up interview. The 12 months prevalence of self-reported COVID-19 associated chemosensory dysfunction was 21.3% (95% CI 16.5-26.7%). Of the 187 patients who complained of COVID-19 associated chemosensory dysfunction at baseline, 130 (69.5%; 95% CI 62.4-76.0%) reported complete resolution of smell or taste impairment, 41 (21.9%) reported a decrease in the severity, and 16 (8.6%) reported the symptom was unchanged or worse 1 year after onset. The risk of persistence was higher for patients reporting a baseline SNOT-22 score ? 4 (OR = 3.32; 95% CI 1.32-8.36) as well as for those requiring ? 22 days for a negative swab (OR = 2.18; 95% CI 1.12-4.27).
Conclusion: A substantial proportion of patients with previous mild-to-moderate symptomatic COVID-19 characterized by new onset of chemosensory dysfunction still complained on altered sense of smell or taste 1 year after the onset.

Keywords: Anosmia; COVID-19; Coronavirus; Outcome; SARS-CoV-2; Smell; Taste.
 
Back
Top Bottom